echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Transsexual pustules psoriasis: Imsidolimab named FDA orphan drug

    Transsexual pustules psoriasis: Imsidolimab named FDA orphan drug

    • Last Update: 2020-07-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Biotech company AnaptysBio announced today that the U.S

    FDA

    has awarded the anti-white interleukin 36 receptor (IL-36R) antibody imsidolimab orphan drug for the treatment of patients with dyslezotic pustulitous psoriasis (GPP)

    Hamza Suria, President and CEO of Anaptys Bio, said, "The orphan drug designation is an important milestone in the imsidolimab program

    We look forward to advancing the clinical development of imsidolimab in GPP, PPP and other clinical indications that may be driven by IL-36R signal disorders."

    GPP is a life-threatening rare disease and currently has no approved treatment

    It is estimated that there are approximately 3,000 cases of GPP patients in the United States

    psoriasis can occur independently or on the basis of the original psoriasis, and the distribution may be generalized or limited

    Generalized pustules psoriasis (GPP) is acute or subacute and manifests itself as a pustules rash widely distributed on the inflamed erythema skin

    Limitation pustules psoriasis mainly affects the palm, foot or finger

    Partially prociatic or limited pustules psoriasis may actually be a new hereditary autoinflammatory disease based on the IL-36 receptor antagonist (IL-36Ra) mutation

    Other specific genetic abnormalities were also found in patients with pustules psoriasis







    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.